Conclina C.A.

What it is

Grupo Conclina is an Ecuadorian healthcare company headquartered in Quito; it owns Hospital Metropolitano, the largest private hospital in the country, Humana S.A. (Ecuador’s third-largest prepaid health plan), and Metrored, a network of outpatient clinics and telemedicine services.

Conclina runs the only hospital in Ecuador accredited by Joint Commission International (JCI) — the same global quality standard applied to leading hospitals in the United States and Europe. Its services span diagnostics, therapeutic support, health check-ups, and a range of specialised medical clinics.

The hospital was conceived in 1977 by a group of Ecuadorian physicians trained in the United States and Europe who wanted to bring international standards home. The company was formally incorporated on 8 May 1979.

Who owns it

When the original American co-founder (AMI, a US hospital chain) decided to exit, it could not sell its shares in what was then a nascent business — so it donated them to the Fundación Metrofraternidad, with two conditions: maintain the hospital’s quality, and use dividends to fund social care for the less privileged. That donation made Metrofraternidad the controlling majority shareholder it remains today.

An alliance with the International Finance Corporation (IFC), the private-sector arm of the World Bank, reinforces governance discipline: IFC requires environmental commitments and sound corporate practice as conditions of its financing. The remaining shares trade publicly on Ecuador’s stock exchange; Conclina’s flagship brand is Hospital Metropolitano, located in northern Quito.

Who runs it

Javier Contreras serves as general manager of Hospital Metropolitano and chief executive of the parent, Grupo Conclina; he has been with the organisation since 2011. Mauricio Rodríguez is the group’s finance director.

The board is described by Contreras as a first-rate governance body with directors drawn from diverse professional backgrounds — an unusual depth for a company of this size in Ecuador’s market. Cecilia de Páez, the longest-serving senior executive at Conclina, also chairs the Fundación Metrofraternidad.

The money, in plain words

Conclina’s shares trade at around $1.97, giving the whole company a market value — its market capitalisation — of roughly $94.5 million. At that price, buyers pay just 3.2 times annual earnings (a price-to-earnings ratio of 3.2×), which is strikingly cheap — the global hospital-sector average is closer to 20×.

For every dollar shareholders have put in, the group earns about 14 cents back per year — a return on equity of 14.42% — reasonable for a capital-heavy hospital operator. The most recent ordinary dividend was $0.14 per share, implying a dividend yield of roughly 7.1% at current prices (our calculation), far above the yields on most Ecuadorian savings instruments.

In 2000 the group acquired Humana S.A., a prepaid health plan with around 215,000 members; combining insurance with hospital and outpatient services mirrors the Kaiser-Permanente model in the US, creating a complementary revenue stream — roughly 58% of group income comes from prepaid plans, and 42% from individual service fees (per IFC case study).

Net revenues grew 3.71% in the most recently available full-year period. Exact annual revenue and net profit figures are not disclosed in publicly available free filings as of the time of writing.

What it is doing now

The IFC partnership continues to shape Conclina’s growth agenda, with the multilateral lender requiring formal environmental and governance commitments in exchange for long-term financing — a discipline that sets the group apart from most private healthcare operators in Ecuador.

The group employs around 2,700 people directly (including physicians) and at least 2,000 indirectly through suppliers and service partners, making it one of Quito’s larger private-sector employers. Its hospital operating subsidiary saw net revenues rise 8.18% in the most recent reported period, outpacing the holding company’s own growth — suggesting that the flagship hospital is gaining share faster than the rest of the group.

What to watch

• Disclosure gap: Conclina publishes only thin public financials for a listed company; the Superintendencia de Compañías filings are the only free primary source for precise revenue and profit. Investors willing to dig into those filings hold an edge.
• Valuation anomaly: A P/E of 3.2× for a JCI-accredited hospital with a 14% return on equity and a 7% dividend yield is either a structural discount for illiquidity in a thin market, or a signal the market knows something the headlines do not — worth investigating either way.
• Succession and governance: The controlling shareholder is a non-profit foundation, not a family or a fund — meaning strategic decisions are insulated from typical market pressures, but leadership transitions (CEO Contreras has been in post since 2011) deserve watching.
• IFC exit or refinancing: IFC made an equity investment in 2015 and a credit line in 2020; any exit or restructuring of those positions would be a material event for minority shareholders.
• Subsidiary reorganisation: Hospital Metropolitano S.A.S. was separately incorporated in August 2021, a structural change whose full implications for the listed holding company’s earnings have not been publicly explained.

This is news, not investment advice.